Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis
Child's Nervous System · 01.05.2026 · 42 (1)
DOI: 10.1007/s00381-026-07264-2 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Child's Nervous System, online erschienen am 01.05.2026. Verfasst von Khushi H Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. khs55@med.miami.edu. Hauptthemen laut MEDLINE: Immunotherapy, Survival Rate, Meningeal Neoplasms, Melanoma. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Purpose
Pediatric primary diffuse leptomeningeal melanomatosis (PDLM) is a rare, aggressive malignancy with no established standard of care. We performed an integrated survival analysis to characterize disease course and identify treatment factors associated with overall survival (OS).
Methods
A systematic literature search of PubMed, Embase, and Scopus (2000–2025) was conducted in accordance with PRISMA guidelines. Eligible studies included patients < 18 years with histopathologically confirmed PDLM per 2021 World Health Organization and Expert Care for Rare Adult Solid Cancers criteria and reported OS and treatment data. Survival was assessed using Kaplan–Meier analyses, with univariable and multivariable Cox proportional hazards regression.
Results
Thirty-three pediatric PDLM cases were identified (57.6% male; median age 10 [IQR 3–14] years). Diagnosis was established via tissue sampling in 72.7%, cerebrospinal fluid cytology in 21.2%, and both in 6.1%. Among 13 patients with molecular testing, 69.2% harbored NRAS mutations. Twenty-four patients (72.7%) received treatment: chemotherapy (70.7%), radiation therapy (41.7%), and immunotherapy (62.5%). Median OS was 5.0 [3.5–7.0] months. On Kaplan–Meier analysis, immunotherapy was associated with improved OS ( p < 0.001), including when combined with radiation ( p = 0.038), chemotherapy ( p = 0.006), or both (p = 0.048). Univariable Cox regression showed immunotherapy to be significantly associated with reduced hazard of death (HR 0.23 [0.10–0.51], p < 0.001). On multivariable analysis, immunotherapy (HR 0.22 [0.10–0.49], p < 0.001) and chemotherapy (HR 0.44 [0.21–0.94], p = 0.035) were independently associated with improved OS.
Conclusion
Pediatric PDLM carries a uniformly poor prognosis. Immunotherapy and chemotherapy were the only treatments independently associated with improved survival, highlighting their central role in management of this rare disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA. khs55@med.miami.edu.
- Hospital de Clinicás, Universidad Nacional de Asunción, San Lorenzo, Paraguay.
- Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.
- Department of Neurological Surgery, Hospital General Pediátrico "Niños de Acosta Ñu", San Lorenzo, Paraguay.
Zitieren
APA
Shah, K. H., Guerrero-Ocampo, M. J., Flecha, I. G., Roach, C. S., Vazquez, S., Servián, D., & Lu, V. M. (2026). Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis. Child's Nervous System, 42(1). https://doi.org/10.1007/s00381-026-07264-2
Vancouver
Shah KH, Guerrero-Ocampo MJ, Flecha IG, Roach CS, Vazquez S, Servián D, et al. Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis. Child's Nervous System. 2026;42(1). doi:10.1007/s00381-026-07264-2
BibTeX
@article{Shah2026,
author = {Shah, Khushi H and Guerrero-Ocampo, Mauricio J and Flecha, Italo G and Roach, Caleigh S and Vazquez, Sima and Servián, Diego and Lu, Victor M},
title = {Impact of chemotherapy and immunotherapy on survival in pediatric primary diffuse leptomeningeal melanomatosis: a systematic review and pooled survival analysis},
journal = {Child's Nervous System},
year = {2026},
volume = {42},
number = {1},
doi = {10.1007/s00381-026-07264-2}
}
EUVIMED